Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
ACTIVE INGREDIENT (IN EACH TABLET)
Chlorpheniramine Maleate 4 mg
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: ■ sneezing ■ runny nose ■ itchy, watery eyes ■ itching of the nose or throat
Ask a doctor before use if you have
■ a breathing problem such as emphysema or chronic bronchitis, ■ glaucoma or ■ trouble urinating due to an enlarged prostate gland
Ask a doctor or pharmacist before use if you
are taking sedatives or tranquilizers
When using this product
■ marked drowsiness may occur ■ avoid alcoholic beverages ■ alcohol, sedatives, and tranquilizers may increase drowsiness ■ be careful when driving a motor vehicle or operating machinery ■ excitability may occur especially in children
If pregnant or breast-feeding,
ask a health professional before use.
Keep out of reach of children.
In case of accidental overdose, contact a doctor or Poison Control Center immediately.
■ take every 4 to 6 hours ■ do not take more than 6 doses in 24 hours ■ adults and children 12 years and over: 1 tablet ■ children 6 to under 12 years: 1/2 tablet ■ children under 6 years: consult a doctor
■ save carton for full directions and warnings ■ store at room temperature ■ do not use if imprinted safety seal under cap is broken or missing
D.&C. Yellow #10 lake, lactose, magnesium stearate, microcrystalline cellulose, stearic acid. May contain starch.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex® (updated Feb 4th, 2015), Cerner Multum™ (updated Feb 17th, 2015), Wolters Kluwer™ (updated Feb 4th, 2015) and others. To view content sources and attributions, refer to our editorial policy.